secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001193125-24-194428
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics Q2 net loss $7.1M; cash $52.3M; SNS-101 dose expansion on track
--------------------------------------------------------------------------------

- Net loss $7.1M vs $9.4M in Q2 2023; R&D $4.6M (-$0.2M), G&A $3.2M (-$2.2M).
- Cash $52.3M, expected to fund operations into Q4 2025.
- Phase 1/2 SNS-101 dose expansion enrollment advancing; initial data Q4 2024; end-of-Phase 1 FDA meeting by year-end.
- ASCO 2024 data showed well-tolerated safety, best-in-class PK, and early clinical activity.
- Appointed Josiah Craver as SVP of Finance, effective July 22, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312524194428/0001193125-24-194428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312524194428/d862389d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-194428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer